Man Group’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-806,484
Closed -$11.7M 2434
2026
Q1
$11.7M Buy
806,484
+406,484
+102% +$5.83M 0.02% 741
2025
Q4
$5.7M Buy
+400,000
New +$3.93M 0.01% 1044
2025
Q2
Sell
-1,018,301
Closed -$8.31M 2234
2025
Q1
$8.31M Buy
1,018,301
+962,860
+1,737% +$8.91M 0.02% 799
2024
Q4
$522K Sell
55,441
-680,887
-92% -$7.08M ﹤0.01% 1658
2024
Q3
$7.86M Buy
+736,328
New +$8.02M 0.02% 845
2023
Q3
Sell
-222,504
Closed -$2.87M 1082
2023
Q2
$2.79M Buy
+222,504
New +$2.64M 0.01% 1086
2023
Q1
Sell
-290,732
Closed -$3.55M 2133
2022
Q4
$3.55M Buy
290,732
+185,635
+177% +$2.09M 0.01% 959
2022
Q3
$1.1M Buy
+105,097
New +$1.17M 0.01% 1253
2022
Q2
Hold
0
1844
2021
Q1
Sell
-213,720
Closed -$4.93M 1899
2020
Q4
$4.93M Sell
213,720
-296,226
-58% -$6.06M 0.02% 819
2020
Q3
$7.2M Sell
509,946
-12,898
-2% -$188K 0.03% 623
2020
Q2
$7.88M Buy
522,844
+288,880
+123% +$3.52M 0.04% 456
2020
Q1
$2.16M Sell
233,964
-56,134
-19% -$534K 0.01% 852
2019
Q4
$2.83M Buy
290,098
+20,401
+8% +$187K 0.01% 1220
2019
Q3
$2.16M Sell
269,697
-21,664
-7% -$235K 0.01% 1219
2019
Q2
$3.64M Buy
291,361
+156,176
+116% +$1.98M 0.01% 1078
2019
Q1
$1.84M Sell
135,185
-11,715
-8% -$143K 0.01% 1372
2018
Q4
$1.41M Sell
146,900
-71,886
-33% -$790K 0.01% 1346
2018
Q3
$2.65M Buy
218,786
+180,351
+469% +$2.52M 0.01% 1298
2018
Q2
$600K Sell
38,435
-239,243
-86% -$3.62M ﹤0.01% 1759
2018
Q1
$4.18M Buy
+277,678
New +$4.23M 0.02% 947

Other funds holding FOLD

Man Group's FOLD Position: Q2 2026 in Review

Man Group sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 806,484 shares — an estimated $11.7M sold.

Man Group first reported a position in FOLD in Q1 2018 and held it in 20 quarters. The position peaked at $11.7M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Man Group reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 806,484 Amicus Therapeutics shares in Q2 2026, an estimated $11.7M.
  • Man Group first reported a position in Amicus Therapeutics in Q1 2018 and held it in 20 quarters.
  • Man Group's Amicus Therapeutics position peaked at $11.7M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.